Ben Adams reports:
The National Institute of Allergy and Infectious Diseases (NIAID) is launching a new clinical trial network to seek out and add thousands of volunteers to major clinical tests for vaccines and monoclonal antibodies against the pandemic.
The so-called COVID-19 Prevention Trials Network (COVPN) was borne from the merger of four existing NIAID-funded clinical trial networks: the HIV Vaccine Trials Network, based in Seattle; the HIV Prevention Trials Network, based in Durham, North Carolina; the Infectious Diseases Clinical Research Consortium, based in Atlanta; and the AIDS Clinical Trials Group, based in Los Angeles.
While continuing to push for that long-sought vaccine for HIV prevention, as well as for other infectious diseases, they will now also focus on their new COVID-19 roles....<<<Read The Full Article Here>>>...
